Waldencast plc (WALD) CEO returns 264,294 RSUs tied to Obagi sale

Rhea-AI Filing Summary

Waldencast plc reported that CEO Michel Brousset returned 264,294 restricted stock units to the company in a disposition to the issuer at $2.00 per unit, leaving 0 units from this award. The repurchase was tied to the sale of its Obagi Medical dermatological skincare and aesthetics business, after which he transitioned to lead Obagi Medical.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Brousset Michel

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Disposition	Restricted Stock Units F1, F2, F3	264,294	$2.00	$529K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.
2. F2. Represents the Issuer's purchase of 264,294 outstanding RSUs held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.
3. F3. On October 30, 2024, the reporting person was granted 396,440 RSUs, which would have vested over a three-year period as follows: (i) 132,146 on October 1, 2025; (ii) 132,147 on October 1, 2026; and (iii) 132,147 on October 1, 2027.

Key Figures

RSUs disposed: 264,294 units Disposition price: $2.00 per unit RSUs after transaction: 0 units +3 more

6 metrics

RSUs disposed 264,294 units Restricted stock units returned to issuer on July 30, 2026

Disposition price $2.00 per unit Price for each RSU in the disposition to Waldencast

RSUs after transaction 0 units Reported holdings from this RSU award following the disposition

Original RSU grant 396,440 units RSUs granted to Michel Brousset on October 30, 2024

First vesting tranche 132,146 units Scheduled to vest on October 1, 2025 from the 2024 RSU grant

Second and third tranches 132,147 units each Scheduled to vest on October 1, 2026 and October 1, 2027

Key Terms

Restricted Stock Units, Class A Ordinary Shares, Disposition to issuer, contingent right

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one Class A"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Class A Ordinary Shares financial

"Each RSU represents a contingent right to receive one Class A ordinary share"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

Disposition to issuer financial

"transaction_code_description": "Disposition to issuer""

contingent right financial

"RSU represents a contingent right to receive one Class A ordinary share"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/07/2026 - 04:12 PM Accepted by SEC EDGAR 08/07/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What insider transaction did Waldencast (WALD) report for CEO Michel Brousset?

Michel Brousset returned 264,294 restricted stock units to Waldencast in a disposition to the issuer at $2.00 per unit. These RSUs were cancelled in connection with the company’s sale of its Obagi Medical dermatological skincare and aesthetics business.

How many Waldencast (WALD) RSUs were involved in the transaction and at what price?

The transaction covered 264,294 restricted stock units at a price of $2.00 per unit. Each RSU represented a contingent right to receive one Class A ordinary share or an equivalent cash value, at the plan administrator’s election.

What are the terms of the Waldencast (WALD) restricted stock units in this report?

Each Waldencast RSU represents a contingent right to receive one Class A ordinary share or equivalent cash value. The RSUs came from a 396,440-unit grant awarded on October 30, 2024, originally scheduled to vest in three annual tranches.

How is the Waldencast (WALD) RSU disposition linked to the Obagi Medical sale?

The company purchased 264,294 outstanding RSUs from Michel Brousset in connection with completing the sale of its Obagi Medical business on July 30, 2026. Effective that date, he transitioned from Waldencast to lead Obagi Medical.

What Waldencast (WALD) RSU holdings remained for Michel Brousset after this transaction?

After the disposition, the reported holding from this RSU award was 0 units. The cancelled units were part of a 396,440-unit grant that had been scheduled to vest over three years beginning October 1, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Brousset Michel

(Last) (First) (Middle)

C/O WALDENCAST PLC

MICHELIN HOUSE, 81 FULHAM ROAD

(Street)

LONDON SW3 6RD

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
Waldencast plc [ WALD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	07/30/2026		D(2)			264,294	(3)	(3)	Class A Ordinary Shares	264,294	$2	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.

2. Represents the Issuer's purchase of 264,294 outstanding RSUs held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.

3. On October 30, 2024, the reporting person was granted 396,440 RSUs, which would have vested over a three-year period as follows: (i) 132,146 on October 1, 2025; (ii) 132,147 on October 1, 2026; and (iii) 132,147 on October 1, 2027.

Remarks:

	/s/ Michel Brousset	08/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)